Publications

Original articles

  • First author, 9 articles
  • Second author, 12 articles
  • Corresponding author*, 7 articles
  1. Yoshimura R, Yamamoto R*, Shinzawa M, Tomi R, Ozaki S, Fujii Y, Ito T, Tanabe K, Moriguchi Y, Isaka Y, and Moriyama T. Drinking frequency modifies an association between salt intake and blood pressure: a cohort study. J Clin Hyperntesn. ( in press)
  2. Yamamoto R*, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y. Incidence of remission and relapse of proteinuria, end-stage kidney disease, mortality, and major outcomes in primary nephrotic syndrome: the Japan Nephrotic Syndrome Cohort Study (JNSCS). Clin Exp Nephrol (in press)
  3. Nishigaki D, Yamamoto R*, Shinzawa M, Kimura Y, Fujii Y, Aoki K, Tomi R, Ozaki S, Yoshimura R, Taneike M, Nakanishi K, Nishida M, Yamauchi-Takihara K, Isaka Y, Moriyama T. Body mass index modifies the association between frequency of alcohol consumption and incidence of hypertension in men but not in women: a retrospective cohort study. Hypertens Res (in press).
  4. Aoki K, Yamamoto R*, Shinzawa M, Kimura Y, Adachi H, Fujii Y, Tomi R, Nakanishi K, Taneike M, Nishida M, Kudo T, Yamauchi-Takihara K, Isaka Y, Moriyama T. Sleep debt and prevalence of proteinuria in subjects with short sleep duration on weekdays: a cross-sectional study. Clin Exp Nephrol 2020; 24: 143–150.
  5. Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S, Matsui I, Hashimoto N, Matsumoto A, Shimada K, Takabatake Y, Takahashi A, Kaimori J-Y, Moriyama T, Yamamoto R, Horio M, Yamamoto K, Sugimoto K, Rakugi H, Isaka Y. A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD. J Am Soc Nephrol 2019; 30: 1073–1085.
  6. Oka T, Hamano T, Sakaguchi Y, Yamaguchi S, Kubota K, Senda M, Yonemoto S, Shimada K, Matsumoto A, Hashimoto N, Mori D, Monden C, Takahashi A, Obi Y, Yamamoto R, Takabatake Y, Kaimori J-Y, Moriyama T, Horio M, Matsui I, Isaka Y. Proteinuria-associated renal magnesium wasting leads to hypomagnesemia: a common electrolyte abnormality in chronic kidney disease. Nephrol Dial Transplant 2019; 34: 1154–1162.
  7. Yamamoto R*, Shinzawa M, Isaka Y, Yamakoshi E, Imai E, Ohashi Y, Hishida A. Sleep Quality and Sleep Duration with CKD are Associated with Progression to ESKD. Clin J Am Soc Nephrol 2018; 13: 1825–1832.
  8. Yamamoto R, Imai E, Maruyama S, Yokoyama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Takeda A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsuruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Nagai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fujimoto S, Okada H, Ishimura E, Kazama JJ, Hiromura K, Mimura T, Suzuki S, Saka Y, Sofue T, Suzuki Y, Shibagaki Y, Kitagawa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y. Regional variations in immunosuppressive therapy in patients with primary nephrotic syndrome: the Japan nephrotic syndrome cohort study. Clin Exp Nephrol 2018; 22: 1266–1280.
  9. Kimura Y, Yamamoto R*, Shinzawa M, Isaka Y, Iseki K, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Asahi K, Moriyama T, Watanabe T. Alcohol consumption and incidence of proteinuria: a retrospective cohort study. Clin Exp Nephrol 2018; 22: 1133–1142.
  10. Nakanishi K, Nishida M, Yamamoto R, Koseki M, Moriyama T, Yamauchi-Takihara K. An implication of Klotho-related molecules in different smoking-related health outcomes between men and women. Clin Chim Acta 2018; 476: 44–48.
  11. Matsumoto A, Nagasawa Y, Yamamoto R, Shinzawa M, Hasuike Y, Kuragano T, Isaka Y, Nakanishi T, Iseki K, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Asahi K, Moriyama T, Watanabe T. The association of alcohol and smoking with CKD in a Japanese nationwide cross-sectional survey. Hypertens Res 2017; 40: 771–778.
  12. Takeshita H, Yamamoto K, Nozato S, Inagaki T, Tsuchimochi H, Shirai M, Yamamoto R, Imaizumi Y, Hongyo K, Yokoyama S, Takeda M, Oguro R, Takami Y, Itoh N, Takeya Y, Sugimoto K, Fukada S-I, Rakugi H. Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice. Sci Rep 2017; 7: 42323.
  13. Nagasawa Y, Yamamoto R, Shinzawa M, Hasuike Y, Kuragano T, Isaka Y, Nakanishi T, Iseki K, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Asahi K, Moriyama T, Watanabe T. Body Mass Index Modifies an Association between Self-Reported Regular Exercise and Proteinuria. J Atheroscler Thromb 2016; 23: 402–412.
  14. Nagasawa Y, Yamamoto R, Shoji T, Shinzawa M, Hasuike Y, Nagatoya K, Yamauchi A, Hayashi T, Kuragano T, Moriyama T, Isaka Y, Nakanishi T. Serum Uric Acid Level Predicts Progression of IgA Nephropathy in Females but Not in Males. PLoS One 2016; 11: e0160828.
  15. Nagasawa Y, Okuzaki D, Muso E, Yamamoto R, Shinzawa M, Iwasaki Y, Iwatani H, Nakanishi T, Isaka Y, Nojima H. IFI27 Is a Useful Genetic Marker for Diagnosis of Immunoglobulin A Nephropathy and Membranous Nephropathy Using Peripheral Blood. PLoS One 2016; 11: e0153252.
  16. Sakaguchi Y, Hamano T, Nakano C, Obi Y, Matsui I, Kusunoki Y, Mori D, Oka T, Hashimoto N, Takabatake Y, Takahashi A, Kaimori J-Y, Moriyama T, Yamamoto R, Horio M, Sugimoto K, Yamamoto K, Rakugi H, Isaka Y. Association between Density of Coronary Artery Calcification and Serum Magnesium Levels among Patients with Chronic Kidney Disease. PLoS One 2016; 11: e0163673.
  17. Kimura T, Hamase K, Miyoshi Y, Yamamoto R, Yasuda K, Mita M, Rakugi H, Hayashi T, Isaka Y. Chiral amino acid metabolomics for novel biomarker screening in the prognosis of chronic kidney disease. Sci Rep 2016; 6: 26137.
  18. Kimura T, Yasuda K, Yamamoto R, Soga T, Rakugi H, Hayashi T, Isaka Y. Identification of biomarkers for development of end-stage kidney disease in chronic kidney disease by metabolomic profiling. Sci Rep 2016; 6: 26138.
  19. Nakanishi K, Nishida M, Yamamoto R, Koseki M, Moriyama T, Yamauchi-Takihara K. Association between N-terminal pro-brain natriuretic peptide and adiponectin in healthy Japanese men. Clin Chim Acta 2016; 460: 138–41.
  20. Nagasawa Y, Okuzaki D, Muso E, Yamamoto R, Shinzawa M, Iwasaki Y, Iwatani H, Nakanishi T, Isaka Y, Nojima H. IFI27 Is a Useful Genetic Marker for Diagnosis of Immunoglobulin A Nephropathy and Membranous Nephropathy Using Peripheral Blood. PLoS One 2016; 11: e0153252.
  21. Iwatani H, Mori D, Yamamoto S, Nakano C, Yamamoto R, Masumura C, Shikina T, Imai T, Inohara H, Rakugi H, Isaka Y. Minimal Change Nephrotic Syndrome Which Was Most Likely Caused by Chronic Sinusitis. Intern Med 2015; 54: 2373–2375.
  22. Iwatani H, Kawabata H, Sakaguchi Y, Yamamoto R, Hamano T, Rakugi H, Isaka Y. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study. Nephron 2015; 130: 8–12.
  23. Iwatani H, Nagasawa Y, Yamamoto R, Iio K, Mizui M, Horii A, Kitahara T, Inohara H, Kumanogoh A, Imai E, Rakugi H, Isaka Y. CD16+CD56+ cells are a potential culprit for hematuria in IgA nephropathy. Clin Exp Nephrol 2015; 19: 216–224.
  24. Saka S, Hirawa N, Oka A, Yatsu K, Hirukawa T, Yamamoto R, Matsusaka T, Imai E, Narita I, Endoh M, Ichikawa I, Umemura S, Inoko H. Genome-wide association study of IgA nephropathy using 23 465 microsatellite markers in a Japanese population. J Hum Genet 2015; 60: 573–580.
  25. Teranishi J, Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Okada N, Moriyama T, Yamauchi A, Tsubakihara Y, Imai E, Rakugi H, Isaka Y. ACE insertion/deletion polymorphism (rs1799752) modifies the renoprotective effect of renin-angiotensin system blockade in patients with IgA nephropathy. J Renin Angiotensin Aldosterone Syst 2015; 16: 633–41.
  26. Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, Kosugi T, Sato W, Tsuboi N, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S. Patient Age and the Prognosis of Idiopathic Membranous Nephropathy. PLoS One 2014; 9: e110376.
  27. Yamaguchi M, Ando M, Yamamoto R, Akiyama S, Kato S, Katsuno T, Kosugi T, Sato W, Tsuboi N, Yasuda Y, Mizuno M, Ito Y, Matsuo S, Maruyama S. Smoking Is a Risk Factor for the Progression of Idiopathic Membranous Nephropathy. PLoS One 2014; 9: e100835.
  28. Ishigami T, Yamamoto R, Nagasawa Y, Isaka Y, Rakugi H, Iseki K, Yamagata K, Tsuruya K, Yoshida H, Fujimoto S, Asahi K, Kurahashi I, Ohashi Y, Moriyama T, Watanabe T. An association between serum γ-glutamyltransferase and proteinuria in drinkers and non-drinkers: a Japanese nationwide cross-sectional survey. Clin Exp Nephrol 2014; 18: 899–910.
  29. Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, Hayashi T, Izumi M, Fukunaga M, Yamauchi A, Tsubakihara Y, Isaka Y. Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: A retrospective cohort study. Clin J Am Soc Nephrol 2014; 9: 1040–1048.
  30. Nagasawa Y, Iio K, Fukuda S, Date Y, Iwatani H, Yamamoto R, Horii A, Inohara H, Imai E, Nakanishi T, Ohno H, Rakugi H, Isaka Y. Periodontal Disease Bacteria Specific to Tonsil in IgA Nephropathy Patients Predicts the Remission by the Treatment. PLoS One 2014; 9: e81636.
  31. Shinzawa M, Yamamoto R, Nagasawa Y, Oseto S, Mori D, Tomida K, Hayashi T, Izumi M, Fukunaga M, Yamauchi A, Tsubakihara Y, Rakugi H, Isaka Y. Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study. Clin Exp Nephrol 2013; 17: 839–47.
  32. Tsujimura A, Miyagawa Y, Takezawa K, Okuda H, Fukuhara S, Kiuchi H, Takao T, Yamamoto R, Nishida M, Yamauchi-Takihara K, Moriyama T, Nonomura N. Is low testosterone concentration a risk factor for metabolic syndrome in healthy middle-aged men? Urology 2013; 82.
  33. Shinzawa M, Yamamoto R, Nagasawa Y, Shoji T, Obi Y, Namba T, Kitamura H, Kaneko T, Okada N, Iwatani H, Yamauchi A, Tsubakihara Y, Imai E, Isaka Y, Rakugi H. Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy. Clin Exp Nephrol 2012; 16: 250–258.
  34. Tsujimura A, Yamamoto R, Okuda H, Yamamoto K, Fukuhara S, Yoshioka I, Kiuchi H, Takao T, Miyagawa Y, Nishida M, Takihara KY-, Moriyama T, Nonomura N. Low serum free testosterone level is associated with carotid intima-media thickness in middle-aged Japanese men. Endocr J 2012; 59: 809–815.
  35. Tatematsu M, Yasuda Y, Morita Y, Sakamoto I, Kurata K, Naruse T, Yamamoto R, Tsuboi N, Sato W, Imai E, Matsuo S, Maruyama S. Complete remission within 2 years predicts a good prognosis after methylprednisolone pulse therapy in patients with IgA nephropathy. Clin Exp Nephrol 2012; 16: 883–891.
  36. Yamamoto R*, Nagasawa Y, Iwatani H, Shinzawa M, Obi Y, Teranishi J, Ishigami T, Yamauchi-Takihara K, Nishida M, Rakugi H, Isaka Y, Moriyama T. Self-reported sleep duration and prediction of proteinuria: A retrospective cohort study. Am J Kidney Dis 2012; 59: 343–355.
  37. Iwatani H, Inoue T, Wada Y, Nagasawa Y, Yamamoto R, Iijima H, Takehara T, Imai E, Rakugi H, Isaka Y. Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy. Biochem Biophys Res Commun 2012; 428: 339–342.
  38. Uehata T, Tomosugi N, Shoji T, Sakaguchi Y, Suzuki A, Kaneko T, Okada N, Yamamoto R, Nagasawa Y, Kato K, Isaka Y, Rakugi H, Tsubakihara Y. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: A cross-sectional study. Nephrol Dial Transplant 2012; 27: 1076–1083.
  39. Yamamoto R, Nagasawa Y, Shoji T, Katakami N, Ohtoshi K, Hayaishi-Okano R, Yamasaki Y, Yamauchi A, Tsubakihara Y, Imai E, Rakugi H, Isaka Y. A candidate gene approach to genetic contributors to the development of IgA nephropathy. Nephrol Dial Transplant 2012; 27: 1020–30.
  40. Furumatsu Y, Nagasawa Y, Shoji T, Yamamoto R, Iio K, Matsui I, Takabatake Y, Kaimori JY, Iwatani H, Kaneko T, Tsubakihara Y, Imai E, Isaka Y, Rakugi H. Urinary type IV collagen in nondiabetic kidney disease. Nephron – Clin Pract 2011; 117: c160-166.
  41. Iwatani H, Iio K, Nagasawa Y, Yamamoto R, Horii A, Okuzaki D, Inohara H, Nojima H, Imai E, Rakugi H, Isaka Y. Microarray Analysis of Tonsils of IgA Nephropathy Patients. Adv Otorhinolaryngol 2011; 72: 75–78.
  42. Imai E, Yamamoto R, Suzuki H, Watanabe T. Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol 2010; 14: 445–452.
  43. Obi Y, Kimura T, Nagasawa Y, Yamamoto R, Yasuda K, Sasaki K, Kitamura H, Imai E, Rakugi H, Isaka Y, Hayashi T. Impact of Age and Overt Proteinuria on Outcomes of Stage 3 to 5 Chronic Kidney Disease in a Referred Cohort. Clin J Am Soc Nephrol 2010; 5: 1558–1565.
  44. Furumatsu Y, Nagasawa Y, Yamamoto R, Iio K, Iwatani H, Matsui I, Takabatake Y, Kawada N, Shoji T, Imai E, Isaka Y, Rakugi H. Specialist care and improved long-term survival of dialysis patients. Nephrol Dial Transplant 2010; 25: 1930–5.
  45. Iio K, Nagasawa Y, Iwatani H, Yamamoto R, Horii A, Okuzaki D, Furumatsu Y, Inohara H, Nojima H, Imai E, Isaka Y, Rakugi H. Microarray analysis of tonsils in immunoglobulin A nephropathy patients. Biochem Biophys Res Commun 2010; 393: 565–570.
  46. Yamamoto R, Nagasawa Y, Shoji T, Iwatani H, Hamano T, Kawada N, Inoue K, Uehata T, Kaneko T, Okada N, Moriyama T, Horio M, Yamauchi A, Tsubakihara Y, Imai E, Rakugi H, Isaka Y. Cigarette smoking and progression of IgA nephropathy. Am J Kidney Dis 2010; 56: 313–324.
  47. Yamamoto R, Nagasawa Y, Shoji T, Inoue K, Uehata T, Kaneko T, Okada T, Yamauchi A, Tsubakihara Y, Imai E, Isaka Y, Rakugi H. A candidate gene approach to genetic prognostic factors of IgA nephropathy–a result of Polymorphism REsearch to DIstinguish genetic factors Contributing To progression of IgA Nephropathy (PREDICT-IgAN). Nephrol Dial Transplant 2009; 24: 3686–94.
  48. Yamamoto R, Nagasawa Y, Marubashi S, Furumatsu Y, Iwatani H, Iio K, Matsui I, Dono K, Imai E, Monden M, Isaka Y. Early plasma exchange for progressive liver failure in recipients of adult-to-adult living-related liver transplants. Blood Purif 2009; 28: 40–46.
  49. Uzu T, Harada T, Namba T, Yamamoto R, Takahara K, Yamauchi A, Kimura G. Thiazide diuretics enhance nocturnal blood pressure fall and reduce proteinuria in immunoglobulin A nephropathy treated with angiotensin II modulators. J Hypertens 2005; 23: 861–5.

Reviews & commentaries

  1. Yuzawa Y, Yamamoto R, Takahashi K, Katafuchi R, Tomita M, Fujigaki Y, Kitamura H, Goto M, Yasuda T, Sato M, Urushihara M, Kondo S, Kagami S, Yasuda Y, Komatsu H, Takahara M, Harabuchi Y, Kimura K, Matsuo S. Evidence-based clinical practice guidelines for IgA nephropathy 2014. Clin Exp Nephrol 2016; 20: 511–535.
  2. Yamamoto R, Rakugi H. ACE Insertion/Deletion Polymorphism and Cardiovascular Effect of Hypercholesterolemia. J Atheroscler Thromb 2015; 22: 338–341.
  3. Nagasawa Y, Yamamoto R, Rakugi H, Isaka Y. Cigarette smoking and chronic kidney diseases. Hypertens Res 2012; 35: 261–265.
  4. Kawada N, Moriyama T, Kitamura H, Yamamoto R, Furumatsu Y, Matsui I, Takabatake Y, Nagasawa Y, Imai E, Wilcox CS, Rakugi H, Isaka Y. Towards developing new strategies to reduce the adverse side-effects of nonsteroidal anti-inflammatory drugs. Clin Exp Nephrol 2012; 16: 25–29.
  5. Nagasawa Y, Yamamoto R, Shigeru M. Therapeutic Apheresis in Liver Transplantation. Transplantationsmedizin 2010; 22: S339.
  6. Yamamoto R, Nagasawa Y. Pathology: Oxford IgA nephropathy classification: Valid for children? Nat Rev Nephrol. 2010. doi:10.1038/nrneph.2010.123
  7. Yamamoto R, Imai E. A novel classification for IgA nephropathy. Kidney Int 2009; 76: 477–480.
  8. Yamamoto R, Imai E. Even partial remission of proteinuria is associated with better renal outcome in patients with IgA nephropathy. Nat Clin Pract Nephrol 2008; 4: 246–7.

Case reports

  1. Inoue K, Nagasawa Y, Yamamoto R, Omori H, Kimura T, Tomida K, Furumatsu Y, Imai E, Isaka Y, Rakugi H. Severe adverse effects of 5-fluorouracil in S-1 were lessened by haemodialysis due to elimination of the drug. Clin Kidney J 2009; 2: 152–154.
  2. Harada T, Uzu T, Namba T, Yamamoto R, Takahara K, Yamauchi A. ANCA-negative pauci-immune crescentic glomerulonephritis complicated with recurrent massive gastrointestinal hemorrhage. Clin Exp Nephrol 2005; 9: 174–178.
  3. Kitamura H, Matsui I, Itoh N, Fujii T, Aizawa M, Yamamoto R, Okuno A, Okazaki Y, Fujita Y, Kuwayama Y, Imai E, Fujii M. Tranexamic acid-induced visual impairment in a hemodialysis patient. Clin Exp Nephrol 2003; 7: 311–314.

Books

  1. Takahashi K, Yamamoto R, Yuzawa Y. Japanese Clinical Practice Guidelines for IgA Nephropathy: Difference from KDIGO Guidelines. In Pathogenesis and Treatment in IgA Nephropathy. Tokyo: Springer Japan, 2016, 251–262.
  2. Yamamoto R. Limitations of RAS Blockade in IgA Nephropathy. In Pathogenesis and Treatment in IgA Nephropathy. Tokyo: Springer Japan, 2016, 263–301.